Document is current
Any future updates will be listed below
-
Authors
Papathanasiou, Theodoros https://orcid.org/0000-0003-2691-9392
Chen, Xi
Carreno, Fernando
McKeown, Astrid
Roy-Ghanta, Sumita
Eccersley, Lydia
Kasinathan, Ravi
Patel, Nashita
Ferron-Brady, Geraldine https://orcid.org/0000-0001-5703-8315
-
Funding
Funding for this research was provided by:
GSK
- License Information
-
More Information
Article History
Received: 19 September 2025
Revised: 24 February 2026
Accepted: 30 March 2026
First Online: 13 April 2026
Competing interests
: TP, GFB, AM, SRG, FC, XC, LE, RV, and NP are employees of and hold financial equities in GSK.
: The DREAMM-6 and DREAMM-7 study protocols were reviewed and approved by institutional review boards or an independent ethics committee at each participating site (detailed previously [ , ]). The trials were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Patients provided signed, informed consent.
: Not applicable.
